SCHEDULE: Actuate Therapeutics: Voss Capital Discloses Stake

Voss Capital and affiliated entities have filed an amended Schedule 13G, reporting beneficial ownership of 7.7% of Actuate Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Voss Capital, LP, along with Voss Value Master Fund, LP, Voss Value-Oriented Special Situations Fund, LP, Voss Advisors GP, LLC, and Travis W. Cocke, have jointly filed an amended Schedule 13G.
• As of March 31, 2026, the reporting persons collectively beneficially own 1,814,263 shares of Actuate Therapeutics, Inc. common stock.
• This represents approximately 7.7% of the total outstanding common stock.
• The filing indicates that Voss Capital, LP, as the investment manager, has the largest beneficial ownership stake among the reporting entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain operational or financial performance updates.

Positives

• The filing clarifies the ownership structure and beneficial interest of Voss Capital and its related entities in Actuate Therapeutics, Inc.
• The reporting persons collectively hold a significant stake of 7.7%, indicating substantial investor confidence or strategic interest.

Risks

• While not explicitly stated as a risk, significant ownership by a single group can sometimes lead to concentrated influence, which may or may not align with the interests of other shareholders.
• The filing does not provide details on the investment strategy or intentions behind this ownership stake, leaving potential future actions open to speculation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding future performance or strategy.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds accumulating significant stakes in publicly traded companies. This filing indicates a notable ownership position by Voss Capital and its affiliates in Actuate Therapeutics, Inc., a development that investors will monitor for potential strategic implications.

Stakeholder Impact

• Shareholders: The increased transparency regarding ownership may influence investor perception and trading activity. The concentration of ownership by Voss Capital could be viewed positively or negatively depending on their investment strategy and its alignment with other shareholders' interests.
• Management and Board of Directors: The significant stake held by Voss Capital may lead to increased engagement or influence on corporate decisions.
• Creditors and Suppliers: No direct impact is indicated by this filing.

Next Steps

• The reporting persons will continue to monitor their investment in Actuate Therapeutics, Inc.
• Further amendments to the Schedule 13G will be filed if there are any material changes in beneficial ownership.

Key Dates

Keywords

Actuate Therapeutics, Schedule 13G, Voss Capital, Voss Value Master Fund, Voss Value-Oriented Special Situations Fund, Travis W. Cocke, Beneficial Ownership, SEC Filing, Common Stock, Investment Management